Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Chin J Integr Med ; 28(7): 627-635, 2022 Jul.
Article in English | MEDLINE | ID: covidwho-1919991

ABSTRACT

OBJECTIVE: To investigate how the National Health Commission of China (NHCC)-recommended Chinese medicines (CMs) modulate the major maladjustments of coronavirus disease 2019 (COVID-19), particularly the clinically observed complications and comorbidities. METHODS: By focusing on the potent targets in common with the conventional medicines, we investigated the mechanisms of 11 NHCC-recommended CMs in the modulation of the major COVID-19 pathophysiology (hyperinflammations, viral replication), complications (pain, headache) and comorbidities (hypertension, obesity, diabetes). The constituent herbs of these CMs and their chemical ingredients were from the Traditional Chinese Medicine Information Database. The experimentally-determined targets and the activity values of the chemical ingredients of these CMs were from the Natural Product Activity and Species Source Database. The approved and clinical trial drugs against these targets were searched from the Therapeutic Target Database and DrugBank Database. Pathways of the targets was obtained from Kyoto Encyclopedia of Genes and Genomes and additional literature search. RESULTS: Overall, 9 CMs modulated 6 targets discovered by the COVID-19 target discovery studies, 8 and 11 CMs modulated 8 and 6 targets of the approved or clinical trial drugs for the treatment of the major COVID-19 complications and comorbidities, respectively. CONCLUSION: The coordinated actions of each NHCC-recommended CM against a few targets of the major COVID-19 pathophysiology, complications and comorbidities, partly have common mechanisms with the conventional medicines.


Subject(s)
COVID-19 Drug Treatment , COVID-19 , Medicine, Chinese Traditional , COVID-19/complications , COVID-19/epidemiology , COVID-19/physiopathology , Comorbidity , Drugs, Chinese Herbal/therapeutic use , Humans , Medicine , SARS-CoV-2
2.
Asian J Pharm Sci ; 16(6): 665-667, 2021 Nov.
Article in English | MEDLINE | ID: covidwho-1321964

ABSTRACT

Graphical Abstract Image, graphical abstract.

SELECTION OF CITATIONS
SEARCH DETAIL